Muutke küpsiste eelistusi

E-raamat: Pharmacology and Vitreoretinal Surgery

Edited by , Series edited by
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 132,60 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Since the advent of pars plana vitrectomy, immense technical advances in the treatment of retinal diseases have been made. However, some mechanically based limitations of vitreoretinal surgery may result in incomplete removal of the vitreous, especially at the vitreoretinal interface and at the vitreous base. Here, pharmacology can be of assistance. For instance, enzymes that cleave the vitreoretinal junction without damaging the retina or which induce liquefaction may be applied. Neuroprotective and antiproliferative agents may hold the promise of preserving neuronal function when the retina is detached or when proliferative vitreoretinopathy or proliferative diabetic retinopathy has developed. Earlier intervention is possible and can save visual function before the retinal cytoarchitecture is destroyed. Consequently, pharmacologic vitreolysis will change the current concepts of treating retinal and macular diseases. This volume is the first comprehensive up-date on pharmacology-assisted vitreoretinal surgery. Researchers in the fields of medical and surgical retina as well as retinal specialists and vitreoretinal surgeons in clinics will benefit from this topical summary.
List of Contributors VII
Preface XI
Gandorfer, A. (Munich)
Pharmacologic Vitreolysis
Objective of Pharmacologic Vitreolysis
1
Gandorfer, A. (Munich)
Vitreous as a Substrate for Vitreolysis
7
Bishop, RN. (Manchester)
Hyaluronidase for Pharmacologic Vitreolysis
20
Narayanan, R. (Hyderabad); Kuppermann, B.D. (Orange, Calif.)
Microplasmin-Assisted Vitrectomy
26
Gandorfer, A. (Munich)
Pharmacologic Vitreodynamics and Molecular Flux
31
Goldenberg, D.T. (Royal Oak, Mich.); Trese, M.T. (Royal Oak, Mich./Rochester, Mich.)
Proliferative Vitreoretinopathy
Glial Cell Changes of the Human Retina in Proliferative Vitreoretinopathy
37
Wickham, L.; Charteris, D.G. (London)
Alkylphosphocholines: A New Approach to Inhibit Cell Proliferation in Proliferative Vitreoretinopathy
46
Eibl, K.H. (Munich); Fisher, S.K.; Lewis, G.P. (Santa Barbara, Calif.)
Diabetic Retinopathy and Diabetic Macular Edema
Neuroprotection for Diabetic Retinopathy
56
Imai, H.; Singh, R.S.J.; Fort, RE.; Gardner, T.W. (Hershey, Pa.)
VEGF Inhibitors and Vitrectomy for Diabetic Vitreoretinopathy
69
Cury Jr, C.E.; Rodrigues, E.B. (Sao Paulo); Meyer, C.H. (Bonn); Farah, M.E. (Sao Paulo)
Age-related Macular Degeneration
Tissue Plasminogen Activator-Assisted Vitrectomy: Surgical Drainage of Submacular Hemorrhage
82
Kamei, M.; Tana, Y. (Suita)
Retinopathy of Prematurity
Anti-Angiogenic Therapy in the Management of Retinopathy of Prematurity
89
Drenser, K.A. (Royal Oak, Mich./Rochester, Mich.)
Author Index 98
Subject Index 99